These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 12239955)

  • 1. Mono-arthritis following intensified interferon beta therapy for chronic hepatitis C.
    Murata K; Shiraki K; Takase K; Nakano T; Tameda Y
    Hepatogastroenterology; 2002; 49(47):1418-9. PubMed ID: 12239955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
    Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
    Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
    Nakamura H; Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S
    Hepatogastroenterology; 2003; 50(49):222-6. PubMed ID: 12630027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy.
    Sezaki H; Arase Y; Tsubota A; Suzuki Y; Kobayashi M; Saitoh S; Suzuki F; Akuta N; Someya T; Ikeda K; Kumada H
    J Gastroenterol; 2003; 38(5):493-500. PubMed ID: 12768394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
    Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
    Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection.
    Tan FU; Cetinkaya H; Erden E; Ulkatan S; Aydin N
    Hepatogastroenterology; 2002; 49(48):1686-7. PubMed ID: 12397766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-beta treatment for chronic hepatitis C.
    Ebinuma H; Saito H; Tada S; Masuda T; Kamiya T; Nishida J; Yoshioka M; Ishii H;
    Hepatogastroenterology; 2004; 51(58):1109-14. PubMed ID: 15239256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interferon therapy in a patient with chronic active hepatitis type C associated with interstitial pneumonia and rheumatoid arthritis: a case report.
    Kurihara T; Abe K; Ishiguro H; Maeda A; Shigemoto M; Yamashita K; Yakoyama I; Ohsako S; Suzuki T; Hara M
    Clin Ther; 1994; 16(6):1028-35. PubMed ID: 7697682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is {beta}-interferon a promising therapeutic option for the management of hepatitis C?
    Hosseini-Moghaddam SM; Mousavi A; Alavian SM
    J Antimicrob Chemother; 2009 Jun; 63(6):1097-103. PubMed ID: 19329508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term interferon therapy for chronic hepatitis C patients with low viral load.
    Sato Y; Tokuue H; Kawamura N; Nezu-Yajima S; Nakajima H; Ishida H; Takahashi S
    Hepatogastroenterology; 2004; 51(58):968-72. PubMed ID: 15239226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
    Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with interferon alpha and beta to chronic hepatitis C.
    Horiike N; Hino H; Tanaka Y; Miyaoka H; Miki S; Yamashita S; Matsuura B; Kubo Y; Ikeda Y; Akbar SM; Masumoto T; Michitaka K; Onji M
    Oncol Rep; 2003; 10(1):157-61. PubMed ID: 12469163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High initial dose combination regimen with interferon-alpha and ribavirin in chronic hepatitis C.
    Kotzev I; Ivanova I; Atanassova M; Atanassova A; Glinkova V; Gancheva D; Shalev I; Manevska B; Krasnaliev I; Tomcheva S
    Hepatogastroenterology; 2003; 50(50):463-6. PubMed ID: 12749248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.
    Cheng PN; Jen CM; Young KC; Chen CY; Lu SN; Wang CS; Chang TT
    Hepatogastroenterology; 2003; 50(50):449-52. PubMed ID: 12749244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case report of interferon beta monotherapy for high hepatitis C viral load in dialysis patients.
    Nakajima F; Fukii M; Kitamura T; Sakaida A; Sakaguchi M; Oka H; Morimoto S; Masaki H; Yamahara H; Shibahara N; Inoue T
    Ther Apher Dial; 2007 Aug; 11(4):306-8. PubMed ID: 17661838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.